Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Short term Debt (2022 - 2025)

Historic Short term Debt for HCW Biologics (HCWB) over the last 4 years, with Q3 2025 value amounting to $6.8 million.

  • HCW Biologics' Short term Debt rose 736.41% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 736.41%. This contributed to the annual value of $6.3 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, HCW Biologics' Short term Debt stood at $6.8 million, which was up 736.41% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, HCW Biologics' Short term Debt registered a high of $38.3 million during Q4 2022, and its lowest value of $67979.0 during Q1 2023.
  • Its 4-year average for Short term Debt is $6.4 million, with a median of $6.2 million in 2025.
  • Its Short term Debt has fluctuated over the past 5 years, first soared by 528792.57% in 2024, then skyrocketed by 736.41% in 2025.
  • Over the past 4 years, HCW Biologics' Short term Debt (Quarter) stood at $38.3 million in 2022, then crashed by 99.69% to $117680.0 in 2023, then skyrocketed by 5265.98% to $6.3 million in 2024, then rose by 7.8% to $6.8 million in 2025.
  • Its Short term Debt was $6.8 million in Q3 2025, compared to $6.4 million in Q2 2025 and $6.2 million in Q1 2025.